CTD402, an allogeneic CAR T-cell therapy, is designed for immediate administration and targets relapsed/refractory T-ALL and ...
The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose ...
The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...
Roberto Mina, MD, discusses the distinguishing factors of the MajesTEC-3 and MajesTEC-9 trials of teclistamab in multiple ...
A novel neoadjuvant therapy combining PD-1 blockade and chemoradiotherapy shows promising results in treating advanced rectal ...
The trial evaluates survival outcomes for recurrent head and neck squamous cell carcinoma post-radiation therapy, comparing ...
Nutritional compromise in cervical cancer patients undergoing chemoradiotherapy predicts poor survival, increased toxicity, ...
Precision medicine in endometrial cancer emphasizes molecular drivers, challenging traditional histopathologic approaches and ...
In an interview with Targeted Oncology, Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses ...
The FDA has granted approval to a larger vial size of nelarabine injection (SH-111) for use in treatment of adult and ...
Bria-IMT demonstrates a median overall survival of 15.6 months, surpassing historical data for heavily pretreated metastatic ...
Abemaciclib improved progression-free survival at 6 months in meningiomas with NF2 or CDK pathway alterations, achieving a 58 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results